DOCSLIB.ORG

Prescription & Illicit Drug Certified Reference Materials

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Prescription & Illicit Drug Certified Reference Materials Prescription & Illicit Drug Certified Reference Materials Many analgesics clinically prescribed to manage chronic pain carry warranted concerns over safety and abuse liability. Further complications can arise from drug-drug interactions when stimulants or other illicit compounds are also abused. Cayman Chemical offers Certified Reference Materials (CRMs) to help identify, confirm, and quantify many of the major opioids, benzodiazepines, psychoactive drugs, and other controlled substances. Our CRMs meet ISO/IEC 17025 and ISO 17034 standards and are sold as quantitative solutions in sealed ampules. Opioid CRMs Benzodiazepine CRMs Item No. Product Name Item No. Product Name ISO60128 Acetyl fentanyl (hydrochloride) (CRM) ISO60185 Alprazolam (CRM) 23060 Acrylfentanyl (hydrochloride) (CRM) ISO60181 Clonazepam (CRM) 25936 Benzyl fentanyl (hydrochloride) (CRM) 25614 Clonazolam (CRM) ISO60178 Buprenorphine (hydrochloride) (CRM) ISO60177 Diazepam (CRM) 19734 Butyryl fentanyl (hydrochloride) (CRM) 28623 Diclazepam (CRM) 19884 Carfentanil (CRM) 20991 Etizolam (CRM) 26637 Crotonyl fentanyl (CRM) 25577 Flualprazolam (CRM) 23603 Cyclopropyl fentanyl (hydrochloride) (CRM) 26352 Flubromazolam (CRM) ISO60197 Fentanyl (hydrochloride) (CRM) 18160 Flurazepam (CRM) 25615 β-methyl Fentanyl (hydrochloride) (CRM) 19391 Midazolam (CRM) 19795 FIBF (hydrochloride) (CRM) 19206 Nimetazepam (CRM) 19826 para-Fluorobutyryl fentanyl (hydrochloride) (CRM) ISO60172 Phenazepam (CRM) 19633 Furanyl fentanyl (hydrochloride) (CRM) ISO60182 Temazepam (CRM) ISO60187 Heroin (CRM) Common benzodiazepines listed, more benzodiazepines and their metabolites and internal standards available online 23540 Methoxyacetyl fentanyl (hydrochloride) (CRM) 18567 Mitragynine (CRM) Request a physical copy of the 19635 Ocfentanil (hydrochloride) (CRM) Benzodiazepine Metabolism 25887 Phenyl fentanyl (hydrochloride) (CRM) 22429 Remifentanil (hydrochloride) (CRM) Wall Poster for your lab! 18660 Tapentadol (hydrochloride) (CRM) BENZODIAZEPINE METABOLISM LAB GUIDE 7-Halogenated-1,4-Benzodiazepines 7-Nitro-1,4-Benzodiazepines Half-Life of Common Benzodiazepines H H O O H O O O Drug (Brand Name) Half-Life (h)+Half-LifePrimary (hr) Metabolite+ (half-life, h)+ N N N N N O O Long Half-Life (effective >24 h)hr) 19397 U-47700 (CRM) OH OH OH R N B O2N N H2N N N N N N Diazepam (Valium) 20-100 20-100Nordiazepam (36-200) A H H R' R CE R R B R Chlordiazepoxide (Librium) (Librium) 5-30 5-30Nordiazepam (36-200) H 1 O O Clorazepate (Tranxene) * * Nordiazepam (36-200) N N Biotransformation Pathway Prazepam (Centrax) * * Nordiazepam (36-200) OH 7 4 R N R N B H H Flurazepam (Dalmane) * * Desalkylflurazepam (40-250) R' R' Intermediate to Short Half-Life (effective 5-24 h)hr) H H Drug O O 1 O O O Nitrazepam (Alodorm) 15-38 15-387-Aminonitrazepam N N N N N OH Flunitrazepam (Rohypnol) 20-30 20-307-Aminoflunitrazepam B O N N O N 7 N 4 H N N H N N R N A 2 2 2 2 Temazepam (Restoril) 8-22 8-22Oxazepam (4-15) 25522 U-48800 (hydrochloride) (CRM) R' R A R CE R B R Bromazepam (Lectopam) 10-20 10-203-hydroxy Bromazepam Lorazepam (Ativan) 10-20 10-20Lorazepam Glucuronide H CH CO H CO R NO Drug Primary Metabolite 3 2 2 2 Alprazolam (Xanax) 6-20 6-20α-hydroxy Alprazolam Examples CE B Oxazepam (Serax) 4-15 4-15Oxazepam Glucuronide O O O H O Etizolam (Etizest) 3.4-7.1 3.4-7.1α-hydroxy Etizolam A B C D E N N N N Examples H Ultra-Short Half-Life (effective <5 h)hr) Cl N Cl N Cl N Br N O H O H O O O N N N N N Midazolam (Versed) <5 <5α-hydroxy Midazolam Cl F Cl OH O2N N O2N N O2N N Triazolam (Halcion) <5 <5α-hydroxy Triazolam N N Phase I Metabolite Diazepam* Diclazepam Fludiazepam Phenazepam H2N O2N F Cl + H O H O H O O R R Approximate half-life data adapted from Greenblatt, D.J., Shader, R.I., Divoll, M., et al. Br. J. Clin. Pharmacol. N N N N Flunitrazepam Nitrazepam Clonazepam 11 (Suppl 1), 11S-16S (1981) and Manchester, K.R., Lomas, E.C., Waters, L., et al. Drug Test Anal. 10(1), 37-53 (2018). OH OH OH *Indicates prodrugs or drug precursors that do not reach the systemic circulation in clinically important amounts. Cl N Cl N Cl N Cl N 23999 U-49900 (CRM) Cl Nordiazepam Lorazepam Oxazepam Temazepam OH H H CO2H NH2 *The primary metabolite of diazepam is nordiazepam Triazolobenzodiazepines Benzodiazepine Prodrugs via phase I demethylation. N N N H O H O H O F G H HO N N N N N N N N N CO2Et CO2H H H H H A A OH Cl N D Cl N CE Cl N R N R N R N Phase II Metabolite F F F Thienodiazepines R' R' R' Ethyl Loflazepate Loflazepate Desalkylflurazepam 24264 U-51754 (hydrochloride) (CRM) N N N HO N N N S N S N HO S N H Examples H O O H O N N N N N N O NH CO2H H N N N N OH H H OH H3C R A R A R N N N N O O N N N N Cl N Cl N Cl N Cl N Cl N O N N Br N HO2C OH 2 CE A OH Cl Cl F Clorazepate Nordiazepam Oxazepam Examples Alprazolam Triazolam Clonazolam Flubromazolam N N N O N N N 8-Nitrotriazolobenzodiazepines can also undergo Hydroxylation Reduction N N N N A E S S S S 19798 Valeryl fentanyl (hydrochloride) (CRM) (MW plus 16) (MW minus 30) Cl Br reduction to 8-aminotriazolobenzodiazepines. O N N N N N Dealkylation What is a Prodrug? Demethylation Sulfation Cl Cl F Cl B F Cl N A prodrug is a drug substance that needs to be (MW minus 14) (MW plus 80) Clotiazepam Etizolam Fluclotizolam Brotizolam converted into the pharmacologically active agent Decarboxylation Glucuronidation View a complete list of parent compounds, metabolites, by metabolic or physiochemical transformation.1 C G Thienodiazepines contain a thiophene ring in place of the (MW minus 44) (MW plus 176) and labeled standards at www.caymanchem.com 1. Drago, D., Pacifici, E., and Bain, S. Chapter 3 Drugs. An overview of FDA regulated products: From Drugs benzene ring of a standard benzodiazepine but exhibit Prazepam and cosmetics to food and tobacco. Pacifici, E. and Bain, S., editors, 1st edition, Academic Press (2018). Acetylation similar activity and pharmacological effects. D Hydrolysis H Common opioids listed, more opioids and their metabolites and internal standards (MW plus 42) © Cayman Chemical Company · Created June 2019 available online Visit www.caymanchem.com/literature 2020 CAYMAN CHEMICAL · 1180 EAST ELLSWORTH ROAD · ANN ARBOR, MI 48108 · USA · (800) 364-9897 WWW.CAYMANCHEM.COM Stimulant and Hallucinogen CRMs Item No. Product Name Item No. Product Name ISO60188 (±)-Amphetamine (hydrochloride) (CRM) 26615 (+)-Methamphetamine (hydrochloride) (CRM) 25523 BZP (hydrochloride) (CRM) 20891 Methylone (hydrochloride) (CRM) ISO60176 Cocaine (CRM) 26279 Mexedrone (hydrochloride) (CRM) 25688 Deschloroketamine (hydrochloride) (CRM) ISO60194 PCP (hydrochloride) (CRM) 27239 bk-DMBDB (hydrochloride) (CRM) 28958 3-methoxy PCP (hydrochloride) (CRM) 29672 Eutylone (hydrochloride) (CRM) 25670 4-methyl Pentedrone (hydrochloride) (CRM) 19389 Ketamine (hydrochloride) (CRM) 27504 Pentylone (hydrochloride) (CRM) ISO60189 (±)-MDA (hydrochloride) (CRM) 24337 N-ethyl Pentylone (hydrochloride) (CRM) 27240 bk-MDEA (hydrochloride) (CRM) 22808 α-Pyrrolidinopentiophenone (hydrochloride) (CRM) ISO60190 3,4-MDMA (hydrochloride) (CRM) 28879 4'-chloro-α-Pyrrolidinovalerophenone (hydrochloride) (CRM) Common psychoactives listed, more psychoactive drugs and their metabolites and internal standards available online Synthetic Cannabinoid CRMs Item No. Product Name Item No. Product Name 27237 AB-CHMINACA (CRM) 17726 5-fluoro CUMYL-PINACA (CRM) ISO60211 AB-FUBINACA (CRM) 27973 JWH 018 (CRM) 19805 4-fluoro ADB (CRM) 22047 MAB-CHMINACA (CRM) 25012 (S)-5-fluoro ADB (CRM) 28186 4-fluoro MDMB-BUTINACA (CRM) 27043 AM2201 (CRM) 18203 PB-22 (CRM) 28624 APP-BUTINACA (CRM) ISO60059 XLR11 (CRM) Common synthetic cannabinoids listed, more synthetic cannabinoids and their metabolites and internal standards available online Sedative and Muscle Relaxant CRMs Barbiturate CRMs Item No. Product Name Item No. Product Name ISO60206 Carisoprodol (CRM) 22912 Amobarbital (CRM) ISO60141 Dextromethorphan (CRM) 22854 Barbital (CRM) 20283 Methaqualone (CRM) 20091 Butalbital (CRM) 20411 Zaleplon (CRM) 20966 Pentobarbital (CRM) 20648 Zolpidem (CRM) 20987 Phenobarbital (CRM) 20397 Zopiclone (CRM) 21707 Secobarbital (CRM) View a full list of internal standards online View a full list of internal standards online Antidepressant CRMs Performance-Enhancing Drug CRMs Item No. Product Name Item No. Product Name 19031 Amitriptyline (hydrochloride) (CRM) ISO60161 Androstenedione (CRM) 25576 Bupropion (hydrochloride) (CRM) 19247 Lorcaserin (hydrochloride) (CRM) 23981 Quetiapine (hemifumarate) (CRM) 21677 Methyldienolone (CRM) 19049 Trazodone (hydrochloride) (CRM) ISO60154 Testosterone (CRM) 25524 Venlafaxine (hydrochloride) (CRM) 9002564 11-keto Testosterone (CRM) View a full list of internal standards online To view a complete list of our Certified Reference Materials, visit us online at www.caymanchem.com/forensics 2020 CAYMAN CHEMICAL · 1180 EAST ELLSWORTH ROAD · ANN ARBOR, MI 48108 · USA · (800) 364-9897 WWW.CAYMANCHEM.COM.
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al
    US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S.
    [Show full text]
  • Understanding Benzodiazephine Use, Abuse, and Detection
    Siemens Healthcare Diagnostics, the leading clinical diagnostics company, is committed to providing clinicians with the vital information they need for the accurate diagnosis, treatment and monitoring of patients. Our comprehensive portfolio of performance-driven systems, unmatched menu offering and IT solutions, in conjunction with highly responsive service, is designed to streamline workflow, enhance operational efficiency and support improved patient care. Syva, EMIT, EMIT II, EMIT d.a.u., and all associated marks are trademarks of General Siemens Healthcare Diagnostics Inc. All Drugs other trademarks and brands are the Global Division property of their respective owners. of Abuse Siemens Healthcare Product availability may vary from Diagnostics Inc. country to country and is subject 1717 Deerfield Road to varying regulatory requirements. Deerfield, IL 60015-0778 Please contact your local USA representative for availability. www.siemens.com/diagnostics Siemens Global Headquarters Global Siemens Healthcare Headquarters Siemens AG Understanding Wittelsbacherplatz 2 Siemens AG 80333 Muenchen Healthcare Sector Germany Henkestrasse 127 Benzodiazephine Use, 91052 Erlangen Germany Abuse, and Detection Telephone: +49 9131 84 - 0 www.siemens.com/healthcare www.usa.siemens.com/diagnostics Answers for life. Order No. A91DX-0701526-UC1-4A00 | Printed in USA | © 2009 Siemens Healthcare Diagnostics Inc. Syva has been R1 R2 a leading developer N and manufacturer of AB R3 X N drugs-of-abuse tests R4 for more than 30 years. R2 C Now part of Siemens Healthcare ® Diagnostics, Syva boasts a long and Benzodiazepines have as their basic chemical structure successful track record in drugs-of-abuse a benzene ring fused to a seven-membered diazepine ring. testing, and leads the industry in the All important benzodiazepines contain a 5-aryl substituent ring (ring C) and a 1,4–diazepine ring.
    [Show full text]
  • Analysis of a Benzodiazepine-Based Drug Using GC-MS 28
    LAAN-E-MS-E028 GCMS Gas Chromatograph Mass Spectrometer Analysis of a Benzodiazepine-Based Drug Using GC-MS 28 Benzodiazepine drugs are commonly used in sleeping aids and tranquilizers, and sometimes in crimes or suicide. Therefore, these chemical substances are often analyzed by forensic laboratories for criminal or academic investigations. This datasheet shows the results from using GC-MS to measure 9 types of benzodiazepine drugs. Analysis Conditions Table 1: Analysis Conditions GC-MS :GCMS-QP2010 Ultra Column : Rxi®-5Sil MS （30 mL. X 0.25 mmI.D., df=0.25 µm, Shimadzu GLC P/N:13623) Glass insert :Silanized splitless insert (P/N: 221-48876-03) [GC] [MS] Vaporization chamber temperature : 260℃ Interface temperature : 280℃ Column oven temperature : 60℃ (2min) -> (10℃/min) -> 320℃ (10min) Ion source temperature : 200℃ Injection mode : Splitless Solvent elution time : 2.0 min Sampling time : 1 min Measurement mode : Scan High pressure injection method: 250 kPa (1.5 min) Mass range : m/z 35-600 Carrier gas : Helium Event time : 0.3 sec Control mode :Linear velocity (45.6 cm/sec) Emission current : 150 µA (high sensitivity) Purge flow rate :3.0 ml/min Sample injection quantity :1.0 µL (x1,000,000) 3.0 3 2.5 2 2.0 1.5 1.0 1 0.5 22.0 23.0 24.0 25.0 26.0 27.0 28.0 min % % 312 55 100.0 1 285 100.0 2 313 109 75.0 75.0 266 259287 342 166 50.0 238 50.0 248 25.0 183 25.0 63 109 0.0 0.0 100 200 300 400 100 200 300 400 % 86 100.0 3 75.0 50.0 25.0 58 99 183 315 387 0.0 100 200 300 400 Fig.
    [Show full text]
  • Recommended Methods for the Identification and Analysis of Fentanyl and Its Analogues in Biological Specimens
    Recommended methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2017 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/53 Original language: English © United Nations, November 2017. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr. Barry Logan, Center for Forensic Science Research and Education, at the Fredric Rieders Family Founda- tion and NMS Labs, United States; Amanda L.A.
    [Show full text]
  • 124.210 Schedule IV — Substances Included. 1
    1 CONTROLLED SUBSTANCES, §124.210 124.210 Schedule IV — substances included. 1. Schedule IV shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. 2. Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below: a. Not more than one milligram of difenoxin and not less than twenty-five micrograms of atropine sulfate per dosage unit. b. Dextropropoxyphene (alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2- propionoxybutane). c. 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers (including tramadol). 3. Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation: a. Alprazolam. b. Barbital. c. Bromazepam. d. Camazepam. e. Carisoprodol. f. Chloral betaine. g. Chloral hydrate. h. Chlordiazepoxide. i. Clobazam. j. Clonazepam. k. Clorazepate. l. Clotiazepam. m. Cloxazolam. n. Delorazepam. o. Diazepam. p. Dichloralphenazone. q. Estazolam. r. Ethchlorvynol. s. Ethinamate. t. Ethyl Loflazepate. u. Fludiazepam. v. Flunitrazepam. w. Flurazepam. x. Halazepam. y. Haloxazolam. z. Ketazolam. aa. Loprazolam. ab. Lorazepam. ac. Lormetazepam. ad. Mebutamate. ae. Medazepam. af. Meprobamate. ag. Methohexital. ah. Methylphenobarbital (mephobarbital).
    [Show full text]
  • S1 Table. List of Medications Analyzed in Present Study Drug
    S1 Table. List of medications analyzed in present study Drug class Drugs Propofol, ketamine, etomidate, Barbiturate (1) (thiopental) Benzodiazepines (28) (midazolam, lorazepam, clonazepam, diazepam, chlordiazepoxide, oxazepam, potassium Sedatives clorazepate, bromazepam, clobazam, alprazolam, pinazepam, (32 drugs) nordazepam, fludiazepam, ethyl loflazepate, etizolam, clotiazepam, tofisopam, flurazepam, flunitrazepam, estazolam, triazolam, lormetazepam, temazepam, brotizolam, quazepam, loprazolam, zopiclone, zolpidem) Fentanyl, alfentanil, sufentanil, remifentanil, morphine, Opioid analgesics hydromorphone, nicomorphine, oxycodone, tramadol, (10 drugs) pethidine Acetaminophen, Non-steroidal anti-inflammatory drugs (36) (celecoxib, polmacoxib, etoricoxib, nimesulide, aceclofenac, acemetacin, amfenac, cinnoxicam, dexibuprofen, diclofenac, emorfazone, Non-opioid analgesics etodolac, fenoprofen, flufenamic acid, flurbiprofen, ibuprofen, (44 drugs) ketoprofen, ketorolac, lornoxicam, loxoprofen, mefenamiate, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, pranoprofen, proglumetacin, sulindac, talniflumate, tenoxicam, tiaprofenic acid, zaltoprofen, morniflumate, pelubiprofen, indomethacin), Anticonvulsants (7) (gabapentin, pregabalin, lamotrigine, levetiracetam, carbamazepine, valproic acid, lacosamide) Vecuronium, rocuronium bromide, cisatracurium, atracurium, Neuromuscular hexafluronium, pipecuronium bromide, doxacurium chloride, blocking agents fazadinium bromide, mivacurium chloride, (12 drugs) pancuronium, gallamine, succinylcholine
    [Show full text]
  • Introduced B.,Byhansen, 16
    LB301 LB301 2021 2021 LEGISLATURE OF NEBRASKA ONE HUNDRED SEVENTH LEGISLATURE FIRST SESSION LEGISLATIVE BILL 301 Introduced by Hansen, B., 16. Read first time January 12, 2021 Committee: Judiciary 1 A BILL FOR AN ACT relating to the Uniform Controlled Substances Act; to 2 amend sections 28-401, 28-405, and 28-416, Revised Statutes 3 Cumulative Supplement, 2020; to redefine terms; to change drug 4 schedules and adopt federal drug provisions; to change a penalty 5 provision; and to repeal the original sections. 6 Be it enacted by the people of the State of Nebraska, -1- LB301 LB301 2021 2021 1 Section 1. Section 28-401, Revised Statutes Cumulative Supplement, 2 2020, is amended to read: 3 28-401 As used in the Uniform Controlled Substances Act, unless the 4 context otherwise requires: 5 (1) Administer means to directly apply a controlled substance by 6 injection, inhalation, ingestion, or any other means to the body of a 7 patient or research subject; 8 (2) Agent means an authorized person who acts on behalf of or at the 9 direction of another person but does not include a common or contract 10 carrier, public warehouse keeper, or employee of a carrier or warehouse 11 keeper; 12 (3) Administration means the Drug Enforcement Administration of the 13 United States Department of Justice; 14 (4) Controlled substance means a drug, biological, substance, or 15 immediate precursor in Schedules I through V of section 28-405. 16 Controlled substance does not include distilled spirits, wine, malt 17 beverages, tobacco, hemp, or any nonnarcotic substance if such substance 18 may, under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C.
    [Show full text]
  • Report on the Investigation Results
    Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail. Report on the Investigation Results February 28, 2017 Pharmaceuticals and Medical Devices Agency I. Overview of Product [Non-proprietary name] See Attachment 1 [Brand name] See Attachment 1 [Approval holder] See Attachment 1 [Indications] See Attachment 1 [Dosage and administration] See Attachment 1 [Investigating office] Office of Safety II 1 Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail. II. Background of the investigation 1. Status in Japan Hypnotics and anxiolytics are prescribed by various specialties and widely used in clinical practice. In particular, benzodiazepine (BZ) receptor agonists, which act on BZ receptors, bind to gamma-aminobutyric acid (GABA)A-BZ receptor complex and enhance the function of GABAA receptors. This promotes neurotransmission of inhibitory systems and demonstrates hypnotic/sedative effects, anxiolytic effects, muscle relaxant effects, and antispasmodic effects. Since the approval of chlordiazepoxide in March 1961, many BZ receptor agonists have been approved as hypnotics and anxiolytics. Currently, hypnotics and anxiolytics are causative agents of drug-related disorders such as drug dependence in Japanese clinical practice. Hypnotics and anxiolitics that rank high in causative agents are BZ receptor agonists for which high frequencies of high doses and multidrug prescriptions have been reported (Japanese Journal of Clinical Psychopharmacology 2013; 16(6): 803-812, Modern Physician 2014; 34(6): 653-656, etc.).
    [Show full text]
  • A Review of the Evidence of Use and Harms of Novel Benzodiazepines
    ACMD Advisory Council on the Misuse of Drugs Novel Benzodiazepines A review of the evidence of use and harms of Novel Benzodiazepines April 2020 1 Contents 1. Introduction ................................................................................................................................. 4 2. Legal control of benzodiazepines .......................................................................................... 4 3. Benzodiazepine chemistry and pharmacology .................................................................. 6 4. Benzodiazepine misuse............................................................................................................ 7 Benzodiazepine use with opioids ................................................................................................... 9 Social harms of benzodiazepine use .......................................................................................... 10 Suicide ............................................................................................................................................. 11 5. Prevalence and harm summaries of Novel Benzodiazepines ...................................... 11 1. Flualprazolam ......................................................................................................................... 11 2. Norfludiazepam ....................................................................................................................... 13 3. Flunitrazolam ..........................................................................................................................
    [Show full text]
  • II.3.4 Benzodiazepines by Hiroshi Seno and Hideki Hattori
    3.4 II.3.4 Benzodiazepines by Hiroshi Seno and Hideki Hattori Introduction Benzodiazepines show antianxiety, hypnotic, anticonvulsant and muscle-relaxant eff ects. Th is group of drugs has wide safety dose ranges; it means that the ratio of the LD50 to the ED50 (therapeutic index) is high. Because of its safety, benzodiazepines are being widely used in the world. Some of benzodiazepines are also being abused or used for so-called “ drug facilitated sexual assault”, and thus they are under the control of the Narcotics and Psychotropics Control Law; in Japan, triazolam abuse has become one of the serious social problems. In this chapter, a GC/MS method for simultaneous analysis of 22 kinds of benzodiazepines listed in > Table 4.1 is described. In addition, the LC/MS analysis of triazolam, and its metabolites 4-hydroxy- triazolam and α-hydroxytriazolam is also presented. GC/MS analysis of benzodiazepines in blood and urine Reagents and their preparation • Th e pure powder of the 22 kinds of benzodiazepines was donated by each pharmaceutical manufacturers according to the authors’ request a (some of benzodiazepines now obtaina- ble from Sigma, St. Louis, MO, USA). • 1 M Sodium bicarbonate solution: a 8.4-g aliquot of sodium bicarbonate is dissolved in distilled water to prepare 100 mL solution. • 2 M Sodium acetate solution: a 27.5-g aliquot of sodium acetate is dissolved in distilled water to prepare 100 mL solution. GC/MS conditions Column: a DB-5 fused silica capillary column (30 m × 0.25 mm i.d., fi lm thickness 0.25 µm, J & W Scientifi c, Folsom, CA, USA).
    [Show full text]
  • Title Continuation and Discontinuation of Benzodiazepine Prescriptions: A
    Continuation and discontinuation of benzodiazepine Title prescriptions: A cohort study based on a large claims database in Japan( Dissertation_全文 ) Author(s) Takeshima, Nozomi Citation 京都大学 Issue Date 2016-05-23 URL https://doi.org/10.14989/doctor.k19890 Right Type Thesis or Dissertation Textversion ETD Kyoto University Psychiatry Research ∎ (∎∎∎∎) ∎∎∎–∎∎∎ Contents lists available at ScienceDirect Psychiatry Research journal homepage: www.elsevier.com/locate/psychres Continuation and discontinuation of benzodiazepine prescriptions: A cohort study based on A large claims database in Japan Nozomi Takeshima, Yusuke Ogawa, Yu Hayasaka, Toshi A Furukawa n Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health, Yoshida Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan article info abstract Article history: Although benzodiazepines (BZDs) are often prescribed to treat a wide range of psychiatric and neuro- Received 29 March 2015 logical conditions, they are also associated with various harms and risks including dependence. However Received in revised form the frequency of its continued use in the real world has not been well studied, especially at longer follow- 15 October 2015 ups. The aim of this study was to clarify the frequency of long-term BZD use among new BZD users over Accepted 15 January 2016 longer follow-ups and to identify its predictors. We conducted a cohort study to examine how frequently new BZD users became chronic users, based on a large claims database in Japan from January 2005 to Keywords: June 2014. We used Cox proportional hazards models to identify potential predictors. A total 84,412 Benzodiazepine patients with new BZD prescriptions were included in our cohort.
    [Show full text]
  • PMDA Alert for Proper Use of Drugs When Using Benzodiazepine
    ■ PMDA Alert for Proper Use of Drugs https://www.pmda.go.jp/english/safety/info-services/drugs/properly- No. 11 March 2017 use-alert/0001.html PMDA Alert for Proper Use of Drugs Pharmaceuticals and Medical Devices Agency No. 11 March 2017 Dependence associated with Benzodiazepine Receptor Agonists [To Patients] This document is for healthcare professionals. If taking the drug, please consult with your physicians or pharmacists. Please don’t reduce the dosage or stop taking the drug on self-judgment. Benzodiazepine receptor agonists have a characteristic of developing physical dependence with long-term use even within an approved dose range, leading to various withdrawal symptoms on dose reduction or discontinuation. <Major withdrawal symptoms> insomnia, anxiety, feeling irritated, headache, queasy/vomiting, delirium, tremor, seizure, etc. Please pay careful attention to the following when using benzodiazepine receptor agonists as hypnotics-sedatives and anxiolytics. Healthcare professionals should avoid long-term use with chronic administration. - Dependence may occur with long-term use even within an approved dose range. - Therapeutic necessity should be carefully considered when continuing administration of the drug. Healthcare professionals should adhere to the dosage and confirm that there is no multiple prescription of similar drugs. - Long-term administration, high-dose administration, or multiple medications increase the risk of developing dependence. - Healthcare professionals should confirm that similar drugs are not prescribed by other medical institutions. Healthcare professionals should reduce the dose or discontinue carefully such as by gradual dose reduction or alternate-days administration when discontinuing the administration. - Sudden discontinuation will develop serious withdrawal symptoms in addition to aggravate primary diseases.
    [Show full text]